CL2021003301A1 - Éster isopropílico de ácido [((1r,2s,5r)-2-isopropil-5-metilciclohexanocarbonil)-amino]-acético para el tratamiento de la tos crónica. - Google Patents
Éster isopropílico de ácido [((1r,2s,5r)-2-isopropil-5-metilciclohexanocarbonil)-amino]-acético para el tratamiento de la tos crónica.Info
- Publication number
- CL2021003301A1 CL2021003301A1 CL2021003301A CL2021003301A CL2021003301A1 CL 2021003301 A1 CL2021003301 A1 CL 2021003301A1 CL 2021003301 A CL2021003301 A CL 2021003301A CL 2021003301 A CL2021003301 A CL 2021003301A CL 2021003301 A1 CL2021003301 A1 CL 2021003301A1
- Authority
- CL
- Chile
- Prior art keywords
- chronic cough
- isopropyl
- amino
- treatment
- acetic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona, en general, con el campo de la terapia. Más específicamente, la presente invención se relaciona con un determinado compuesto, éster isopropílico de ácido [((1R,2S,5R)-2-isopropil-5-metil-ciclohexanocarbonil)-amino]-acético (al que también se hace referencia en la presente como “AX-8” o “Gly-O-iPr”), como se describe en la presente, para el uso en un método de tratamiento del cuerpo humano o animal mediante terapia, más específicamente, para usar en un método de tratamiento de la tos crónica (CC), inclusive, por ejemplo, tos crónica refractaria (RCC) y tos crónica idiopática (ICC), como se describe en la presente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1908219.7A GB201908219D0 (en) | 2019-06-10 | 2019-06-10 | Therapeutic use of a compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021003301A1 true CL2021003301A1 (es) | 2022-08-19 |
Family
ID=67386245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021003301A CL2021003301A1 (es) | 2019-06-10 | 2021-12-10 | Éster isopropílico de ácido [((1r,2s,5r)-2-isopropil-5-metilciclohexanocarbonil)-amino]-acético para el tratamiento de la tos crónica. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US12167995B2 (es) |
| EP (2) | EP3980003B1 (es) |
| JP (1) | JP7181426B2 (es) |
| KR (2) | KR102836060B1 (es) |
| CN (1) | CN114007601B (es) |
| AU (2) | AU2020293622B2 (es) |
| BR (1) | BR112021024927A2 (es) |
| CA (1) | CA3143094C (es) |
| CL (1) | CL2021003301A1 (es) |
| DK (1) | DK3980003T3 (es) |
| EA (1) | EA202193006A1 (es) |
| ES (1) | ES2973546T3 (es) |
| FI (1) | FI3980003T3 (es) |
| GB (1) | GB201908219D0 (es) |
| HR (1) | HRP20240312T1 (es) |
| HU (1) | HUE065581T2 (es) |
| IL (1) | IL288874A (es) |
| JO (1) | JOP20210315B1 (es) |
| LT (1) | LT3980003T (es) |
| MA (1) | MA56105B1 (es) |
| MD (1) | MD3980003T2 (es) |
| MX (1) | MX2021014761A (es) |
| MY (1) | MY209641A (es) |
| PH (1) | PH12021553093A1 (es) |
| PL (1) | PL3980003T3 (es) |
| PT (1) | PT3980003T (es) |
| RS (1) | RS65224B1 (es) |
| SI (1) | SI3980003T1 (es) |
| SM (1) | SMT202400198T1 (es) |
| WO (1) | WO2020249607A1 (es) |
| ZA (1) | ZA202109580B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250288583A1 (en) * | 2024-03-14 | 2025-09-18 | Edward Tak Wei | Treatment of Mucus Hypersecretion |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7189760B2 (en) * | 2004-04-02 | 2007-03-13 | Millennium Specialty Chemicals | Physiological cooling compositions containing highly purified ethyl ester of N-[[5-methyl-2-(1-methylethyl) cyclohexyl] carbonyl]glycine |
| EP1761543A1 (de) * | 2004-06-22 | 2007-03-14 | Basf Aktiengesellschaft | Verwendung von 6-(2-tolyl)-triazolopyrimidinen als fungizide, neue 6-(2-tolyl)-triazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung |
| KR20070116133A (ko) * | 2005-03-29 | 2007-12-06 | 에드워드 택 웨이 | Ｎ-알킬카르보닐-아미노산 에스테르 및ｎ-알킬카르보닐-아미노 락톤 화합물 및 이의 용도 |
| CA2819466C (en) | 2010-12-06 | 2019-11-26 | Axalbion Sa | [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester and related compounds and their use in therapy |
| US8426463B2 (en) * | 2011-04-04 | 2013-04-23 | Edward T. Wei | [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester and related compounds and their use in therapy |
| WO2013117504A1 (en) * | 2012-02-06 | 2013-08-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Pi3k inhibitors for treating cough |
| JP2016535027A (ja) * | 2013-10-22 | 2016-11-10 | エドワード タク ウェイＷＥＩ， Ｅｄｗａｒｄ Ｔａｋ | 非角化重層上皮（ＮＫＳＥ）組織の不快感の治療用局所薬としての１−ジ（ｓｅｃ−ブチル）−ホスフィノイル−ペンタン（ＤＡＰＡ−２−５） |
| JP7412328B2 (ja) | 2017-07-24 | 2024-01-12 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| SG11202011010YA (en) | 2018-05-15 | 2020-12-30 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
-
2019
- 2019-06-10 GB GBGB1908219.7A patent/GB201908219D0/en not_active Ceased
-
2020
- 2020-06-10 KR KR1020217042443A patent/KR102836060B1/ko active Active
- 2020-06-10 EP EP20732556.4A patent/EP3980003B1/en active Active
- 2020-06-10 LT LTEPPCT/EP2020/066065T patent/LT3980003T/lt unknown
- 2020-06-10 ES ES20732556T patent/ES2973546T3/es active Active
- 2020-06-10 SI SI202030384T patent/SI3980003T1/sl unknown
- 2020-06-10 MY MYPI2021007360A patent/MY209641A/en unknown
- 2020-06-10 MX MX2021014761A patent/MX2021014761A/es unknown
- 2020-06-10 PL PL20732556.4T patent/PL3980003T3/pl unknown
- 2020-06-10 MD MDE20220407T patent/MD3980003T2/ro unknown
- 2020-06-10 JP JP2021571758A patent/JP7181426B2/ja active Active
- 2020-06-10 MA MA56105A patent/MA56105B1/fr unknown
- 2020-06-10 WO PCT/EP2020/066065 patent/WO2020249607A1/en not_active Ceased
- 2020-06-10 BR BR112021024927A patent/BR112021024927A2/pt unknown
- 2020-06-10 SM SM20240198T patent/SMT202400198T1/it unknown
- 2020-06-10 KR KR1020257023720A patent/KR20250111405A/ko active Pending
- 2020-06-10 EA EA202193006A patent/EA202193006A1/ru unknown
- 2020-06-10 EP EP23214305.7A patent/EP4342533A3/en active Pending
- 2020-06-10 CN CN202080045857.9A patent/CN114007601B/zh active Active
- 2020-06-10 AU AU2020293622A patent/AU2020293622B2/en active Active
- 2020-06-10 HU HUE20732556A patent/HUE065581T2/hu unknown
- 2020-06-10 FI FIEP20732556.4T patent/FI3980003T3/fi active
- 2020-06-10 DK DK20732556.4T patent/DK3980003T3/da active
- 2020-06-10 CA CA3143094A patent/CA3143094C/en active Active
- 2020-06-10 PH PH1/2021/553093A patent/PH12021553093A1/en unknown
- 2020-06-10 HR HRP20240312TT patent/HRP20240312T1/hr unknown
- 2020-06-10 US US17/618,394 patent/US12167995B2/en active Active
- 2020-06-10 PT PT207325564T patent/PT3980003T/pt unknown
- 2020-06-10 RS RS20240225A patent/RS65224B1/sr unknown
-
2021
- 2021-11-25 ZA ZA2021/09580A patent/ZA202109580B/en unknown
- 2021-11-28 JO JOJO/P/2021/0315A patent/JOP20210315B1/ar active
- 2021-12-09 IL IL288874A patent/IL288874A/en unknown
- 2021-12-10 CL CL2021003301A patent/CL2021003301A1/es unknown
-
2025
- 2025-07-02 AU AU2025205040A patent/AU2025205040A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202100009A (es) | Métodos para reducir la necesidad de revascu | |
| MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| CR20240120A (es) | Compuesto inductor de la degradación de PLK1 novedoso | |
| CO2021015264A2 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| BR112022007677A2 (pt) | L-asparaginase recombinante | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| CR20120190A (es) | INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA | |
| BR112022012473A2 (pt) | Composição de tratamento capilar, e, métodos para tratar cabelo, para melhorar a condição do cabelo e para diminuir o ph do cabelo | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| BR112015022577A2 (pt) | moduladores ship1 e métodos relacionados a esse | |
| ECSP24003395A (es) | Sal | |
| CO6592101A2 (es) | Metodos para tratar ulceras de pie de diabetico | |
| ECSP21088111A (es) | Analogos de 3(5metil1,3tiazol2il)n{(1r)1[2(trifluormetil)pirimidin5il]etil}benzamida | |
| CL2023000943A1 (es) | Formas cristalinas de un compuesto farmacéutico. | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| BR112019005456A2 (pt) | composição farmacêutica e método para tratamento de esteatose hepática não alcoólica | |
| BR112022003659A2 (pt) | Composições e métodos de tratamento de doenças vasculares | |
| MX2023003846A (es) | Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo. | |
| MX2023012851A (es) | Métodos de tratamiento y seguimiento de la enfermedad de parkinson. | |
| BR112022007718A2 (pt) | Composição farmacêutica, e, métodos de tratamento de um sujeito em necessidade e para produção de uma composição farmacêutica sólida | |
| PE20220486A1 (es) | Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico | |
| CL2022003435A1 (es) | Métodos de tratamiento del complejo de esclerosis tuberosa | |
| PY2217333A (es) | Compuestos que tienen tetrahidroindolizina-1-carboxamida como inhibidores de bcl-2 |